Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis

Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from a hypersensitivity response to Aspergillus fumigatus, although the pathogenesis of the disease is unknown and its prevalence in cystic fibrosis (CF) is still poorly defined. Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF) on 12,447 CF patients gathered from 224 CF centres in nine European countries were analysed. The ERCF definition of ABPA diagnosis is a positive skin test and serum precipitins to A. fumigatus, together with serum immunoglobulin (Ig)E levels >1,000 U x mL(-1) and additional clinical or laboratory parameters. The overall prevalence of ABPA in the ERCF population was 7.8% (range: 2.1% in Sweden to 13.6% in Belgium). Prevalence was low <6 yrs of age but was almost constant approximately 10% thereafter. No sex differences were observed. ABPA affected 8.0% of patients with a deltaF508/deltaF508 genotype and 5-6% with deltaF508/G551D, deltaF508/G542X and deltaF508/N1303K genotypes. ABPA patients presented a lower forced expiratory volume in one second (FEV1) than those without ABPA at any age and the prevalence ranged from 6.6% in patients with FEV1 > or =20-12.9% in those with FEV1 <40%. ABPA was associated with higher rates of microbial colonization, pneumothorax and massive haemoptysis, and with higher IgG serum levels and poorer nutritional status. A mixed model regression analysis of lung function showed that FEVI decline during the follow-up period was not substantially different in ABPA patients compared with non-ABPA patients for any subgroups based on age or disease severity at enrollment. To conclude, allergic bronchopulmonary aspergillosis is a frequent complication in cystic fibrosis patients, particularly after the age of 6 yrs, and it is generally associated with a poorer clinical condition. However, any clear independent influence of allergic bronchopulmonary aspergillosis on the rate of lung function decline in the short term was not shown.

This article has been cited by other articles:

				P. Latzin, D. Hartl, N. Regamey, U. Frey, M. H. Schoeni, and C. Casaulta Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis Eur. Respir. J., January 1, 2008; 31(1): 36 - 42. [Abstract] [Full Text] [PDF]

				R. Kraemer, N. Delosea, P. Ballinari, S. Gallati, and R. Crameri Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1211 - 1220. [Abstract] [Full Text] [PDF]

				J. B. Allard, M. E. Poynter, K. A. Marr, L. Cohn, M. Rincon, and L. A. Whittaker Aspergillus fumigatus Generates an Enhanced Th2-Biased Immune Response in Mice with Defective Cystic Fibrosis Transmembrane Conductance Regulator J. Immunol., October 15, 2006; 177(8): 5186 - 5194. [Abstract] [Full Text] [PDF]

				H. Kunst, M. Wickremasinghe, A. Wells, and R. Wilson Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis Eur. Respir. J., August 1, 2006; 28(2): 352 - 357. [Abstract] [Full Text] [PDF]

				D. Shoseyov, K. G. Brownlee, S. P. Conway, and E. Kerem Aspergillus bronchitis in cystic fibrosis. Chest, July 1, 2006; 130(1): 222 - 226. [Abstract] [Full Text] [PDF]

				S. P. Conway, C. Etherington, D. G. Peckham, K. G. Brownlee, A. Whitehead, and H. Cunliffe Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis J. Antimicrob. Chemother., May 1, 2004; 53(5): 841 - 847. [Abstract] [Full Text] [PDF]

				I M Balfour-Lynn, U Mohan, A Bush, and M Rosenthal Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children Arch. Dis. Child., April 1, 2004; 89(4): 315 - 319. [Abstract] [Full Text] [PDF]

				L. Saiman and J. Siegel Infection Control in Cystic Fibrosis Clin. Microbiol. Rev., January 1, 2004; 17(1): 57 - 71. [Abstract] [Full Text] [PDF]

				H Witt Chronic pancreatitis and cystic fibrosis Gut, May 1, 2003; 52(90002): ii31 - 41. [Abstract] [Full Text]

				M. Helmi, R. B. Love, D. Welter, R. D. Cornwell, and K. C. Meyer Aspergillus Infection in Lung Transplant Recipients With Cystic Fibrosis: Risk Factors and Outcomes Comparison to Other Types of Transplant Recipients Chest, March 1, 2003; 123(3): 800 - 808. [Abstract] [Full Text] [PDF]

				I M Balfour-Lynn and J S Elborn "CF asthma": what is it and what do we do about it? Thorax, August 1, 2002; 57(8): 742 - 748. [Abstract] [Full Text] [PDF]

				M. Skov, K.M. Main, I.B. Sillesen, J. Muller, C. Koch, and S. Lanng Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide Eur. Respir. J., July 1, 2002; 20(1): 127 - 133. [Abstract] [Full Text] [PDF]

				W. H. Nikolaizik, M. Weichel, K. Blaser, and R. Crameri Intracutaneous Tests with Recombinant Allergens in Cystic Fibrosis Patients with Allergic Bronchopulmonary Aspergillosis and Aspergillus Allergy Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 916 - 921. [Abstract] [Full Text] [PDF]

				L. Maiz, M. Cuevas, S. Quirce, J. F. Canon, A. Pacheco, A. Sousa, and H. Escobar Serologic IgE Immune Responses Against Aspergillus fumigatus and Candida albicans in Patients With Cystic Fibrosis Chest, March 1, 2002; 121(3): 782 - 788. [Abstract] [Full Text] [PDF]

				J. Navarro, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, G. Mastella, B. Strandvik, and S.G. McKenzie Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF Eur. Respir. J., August 1, 2001; 18(2): 298 - 305. [Abstract] [Full Text] [PDF]

				G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, B. Strandvik, and S.G. McKenzie Allergic bronchopulmonary aspergillosis in cystic fibrosis Eur. Respir. J., May 1, 2001; 17(5): 1052 - 1053. [Full Text] [PDF]

				J.A. Kastelik, I. Aziz, A.E. Redington, and A.H. Morice Allergic bronchopulmonary aspergillosis in cystic fibrosis Eur. Respir. J., January 1, 2001; 17(1): 156 - 156. [Full Text] [PDF]